Vuong Trieu
- Biomaterials top 1%
- Nanoparticle-Based Drug Delivery 9
- Oncology top 1%
- Cancer Treatment and Pharmacology 28
- Pancreatic and Hepatic Oncology Research 9
- Cancer Cells and Metastasis 7
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism 12
- Pharmaceutical Science top 2%
- Molecular Biology top 10%
- TGF-β signaling in diseases 9
-
- Lipoproteins and Cardiovascular Health 12
-
- Cancer Research and Treatments 8
- Co-authors
- Neil DesaiPatrick Soon‐ShiongFatih M. UckunMichael HawkinsTapas DeAndrew YangWalter J. McConathyB Damascelli
- Cited by
- BiomaterialsOncologyCancer Research
- Partner nations
- United StatesItalyRussia
In The Last Decade
Vuong Trieu
82 papers receiving 4.0k citations
Hit Papers
Peers
Comparison fields: 5 of 111
- Biomaterials 969
- Oncology 2.0k
- Cancer Research 889
- Pharmaceutical Science 148
- Molecular Biology 1.2k
Countries citing papers authored by Vuong Trieu
This map shows the geographic impact of Vuong Trieu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vuong Trieu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vuong Trieu more than expected).
Fields of papers citing papers by Vuong Trieu
This network shows the impact of papers produced by Vuong Trieu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vuong Trieu. The network helps show where Vuong Trieu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Vuong Trieu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 6 | |
| 5 | 2021 | 0 | |
| 6 | 2020 | 1 | |
| 7 | 2019 | 26 | |
| 8 | 2019 | 30 | |
| 9 | 2018 | 21 | |
| 10 | 2017 | 4 | |
| 11 | 2014 | 2 | |
| 12 | 2014 | 1 | |
| 13 | Pharmacokinetic and ADME study of nanoparticle albumin-bound 17AAG (nab-17AAG) in mice | 2008 | 2 |
| 14 | Toxicology and safety pharmacology of nanoparticle albumin-bound (nab) rapamycin (ABI-009) | 2008 | 1 |
| 15 | Characterization and in vitro/in vivo dissolution of nab-paclitaxel nanoparticles | 2008 | 7 |
| 16 | SPARC overexpression enhances sensitivity to nab-paclitaxel in vivo | 2007 | 4 |
| 17 | Nanoparticle albumin-bound (nab) rapamycin as an anticancer agent | 2007 | 5 |
| 18 | Investigation of chemotherapy-induced tumor angiogenesis: Rationale for combination of nab-paclitaxel with anti-VEGF therapy | 2007 | 1 |
| 19 | 2000 | 9 | |
| 20 | 1994 | 18 |
About Vuong Trieu
Vuong Trieu is a scholar working on Cancer Research, Oncology and Genetics, having authored 92 papers that have together received 4.1k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (28 papers), Lipoproteins and Cardiovascular Health (12 papers), Cancer, Hypoxia, and Metabolism (12 papers), Pancreatic and Hepatic Oncology Research (9 papers), Nanoparticle-Based Drug Delivery (9 papers), TGF-β signaling in diseases (9 papers), Cancer Research and Treatments (8 papers) and Cancer Cells and Metastasis (7 papers). The work is most often cited by research in Biomaterials (969 citations), Oncology (2.0k citations) and Cancer Research (889 citations). Vuong Trieu has collaborated with scholars based in United States, Italy and Russia. Frequent co-authors include Neil Desai, Patrick Soon‐Shiong, Fatih M. Uckun, Michael Hawkins, Tapas De, Andrew Yang, Walter J. McConathy, B Damascelli, Daniel D. Von Hoff and Leslie Louie.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.